Event Details
January 01, 2017
Description
AES 2017 (American Epilepsy Society meeting) where GW presented pooled analysis.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Gwadar | location | 2 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024907.jpg
This document is page 91 of a Cowen Collaborative Insights investment report dated February 25, 2019. It details the clinical trial results and investor analysis for the drug Epidiolex, specifically focusing on its efficacy in treating seizures (Dravet and LGS) with and without the concomitant use of clobazam, and noting that the drug is effective on its own. While part of a document production marked 'HOUSE_OVERSIGHT', the content is strictly pharmaceutical financial analysis and does not mention Jeffrey Epstein directly.
Related Events
Events with shared participants
Phase II 100 patient placebo controlled trial for GW's CBDV drug began.
2018-12-01 • Unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event